share_log

Aphex BioCleanse Systems, Inc (OTC:SNST) Suspends Director Scott Smith

Aphex BioCleanse Systems, Inc (OTC:SNST) Suspends Director Scott Smith

Aphex生物清潔系統公司(場外交易代碼:SNST)暫停董事交易斯科特·史密斯
GlobeNewswire ·  2022/02/19 01:50

PITTSFORD, NY, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Aphex BioCleanse Systems, Inc. (OTC Pink: SNST), a forward-thinking, publicly traded company, announces it has come to the attention of the Board of Directors of Aphex BioCleanse Systems, Inc., that on February 10, 2022, Board Member Scott Smith filed a legal action in the U.S. District Court for Massachusetts against the Company and two of its Directors.

環球通訊社紐約州匹茲福德2022年2月18日電Aphex BioCleanse Systems,Inc.(場外交易代碼:SNST)是一傢俱有前瞻性的上市公司,該公司宣佈已經引起Aphex BioCleanse Systems,Inc.董事會的注意,董事會成員斯科特·史密斯於2022年2月10日向美國馬薩諸塞州地區法院提起訴訟,起訴該公司及其兩名董事。

The object of the lawsuit is not to benefit the Company's shareholders but to financially benefit Scott Smith individually, and the litigation potentially damages shareholder interests. This litigation also clearly violates the "Schoon Doctrine", (Schoon v. Smith, No. 554, 2006 Del. Feb. 12, 2008)

訴訟的目的不是讓公司的股東受益,而是讓斯科特·史密斯個人在財務上受益,訴訟可能會損害股東的利益。這起訴訟也明顯違反了“肖恩原則”(Schoon訴Smith,No.554,2006年5月)。2008年2月12日)

The Schoon Doctrine supports that acting Directors cannot bring actions against the Company, its Directors and/or Officers that are not in the interests of the Company and as such breaches the fiduciary responsibility of each the Director to the shareholders.

肖恩主義支持代理董事不得對本公司、其董事和/或高級管理人員提起不符合本公司利益的訴訟,因此違反了董事各自對股東的受信責任。

Accordingly, the Chairman of the Aphex Board of Directors, Thomas Fitzgerald has determined, effective immediately, to suspend Scott Smith from any, and all duties as a Board Director, pending a complete investigation of this matter and allow a review by the other full Board members.

因此,Aphex董事會主席託馬斯·菲茨傑拉德決定,在對此事進行全面調查並允許其他董事會成員進行審查之前,立即暫停斯科特·史密斯作為董事公司董事會成員的所有職務。

Investor Contact:
Jon Olson, CEO
Milestone Management Services
Jon@milestonemanagementservicesllc.com
702-217-9518

投資者聯繫方式:
喬恩·奧爾森(Jon Olson),首席執行官
里程碑管理服務
郵箱:jon@milestonemanagementservicesllc.com
702-217-9518

About Aphex BioCleanse Systems, Inc.
Aphex BioCleanse Systems, Inc. is the developer of the world's first proprietary non-alcohol, non-toxic, hydrogen-based cleaning technology, and has been producing germ killing solutions for over 10 years. The technology, called Hy-IQ® Water, has a unique method of sanitizing that uses hydrogen ions traveling nearly at the speed of light to breach the cell walls of exoskeleton germs. "We Kill Germs with Physics, Not Chemistry" is a tagline that expresses their commitment to the environment by providing non-Chemical solutions to the spread of dangerous pathogens.  Killing the most dangerous germs on the planet, while meeting the EPA's definition of "Water" is revolutionary. With world leading teams and technology, Aphex is doing its part to make the world a safer place. To find out more about Aphex and their technologies, visit: Aphex BioCleanse Systems, Inc. - Superior Sanitization (aphexus.com).

Aphex BioCleanse系統公司簡介
Aphex BioCleanse Systems,Inc.是世界上第一個無酒精、無毒、基於氫氣的專有清潔技術的開發商,生產殺菌解決方案已有10多年的歷史。這項名為Hy-IQ®Water的技術有一種獨特的消毒方法,它使用氫離子以接近光速的速度移動,以突破外骨骼細菌的細胞壁。“我們用物理而不是化學殺死細菌”是一句標語,通過為危險病原體的傳播提供非化學解決方案來表達他們對環境的承諾。殺滅地球上最危險的細菌,同時滿足環境保護局對“水”的定義是革命性的。憑藉世界領先的團隊和技術,Aphex正在為讓世界變得更安全而儘自己的一份力量。欲瞭解更多有關Aphex及其技術的信息,請訪問:Aphex BioCleanse Systems,Inc.-Superior Sanitiization(apexus.com)。

Forward Looking Statements
This current press release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future, including but not limited to, any products sold or cash flow from operations. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with distribution and difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

前瞻性陳述
本新聞稿包含“前瞻性陳述”,這一術語在1933年“美國證券法”第27A節和1934年“證券交易法”第21E節中有定義。本新聞稿中非純粹歷史性的陳述均為前瞻性陳述,包括有關對未來的信念、計劃、預期或意圖的任何陳述,包括但不限於已售出的任何產品或來自運營的現金流。由於許多因素,實際結果可能與任何前瞻性陳述中預測的結果不同。這些因素除其他外,包括與分銷有關的固有不確定性,以及與以可接受的條件獲得融資有關的困難。這些前瞻性陳述是截至本新聞稿發佈之日作出的,我們沒有義務更新前瞻性陳述,也沒有義務更新實際結果可能與前瞻性陳述中預測的結果不同的原因。儘管我們相信本新聞稿中包含的信念、計劃、預期和意圖是合理的,但不能保證這些信念、計劃、預期或意圖將被證明是準確的。投資者應參考本文提供的所有信息,還應參考我們上一財年的最新年度報告、季度報告以及不定期向美國證券交易委員會提交的其他定期報告。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論